24‐hour blood pressure control by once‐daily administration of irbesartan assessed by ambulatory blood pressure monitoring

Journal of Hypertension

Volumn 15, Issue 12, 1997, Pages 1511-1518

  Fogari, Roberto ^a   Ambrosoli, Sergio ^a   Corradi, Luca ^a   Esposti, Ezio Degli ^a   Mos, Lucio ^a   Nami, Renato ^a   Nicrosini, Francesco ^a   Pessina, Achille C ^a   Salvetti, Antonio ^a   Vaccarella, Alvaro ^a   Zanchetti, Alberto ^a   Martin, Ann ^a   Reeves, Richard A ^a  

^a NONE

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptor antagonist; Hypertension; Irbesartan; Placebo controlled trial

Indexed keywords

IRBESARTAN; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 6844258187     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199715120-00020     Document Type: Article

References (19)

1. Parati G, Ravogli A, Frattola A, Groppelli A, Ulian L, Santucciu C, et al.: Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens 1994, 12 (suppl 5):S35-S40.
2. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993, 265:826-834.
3. Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF: Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension [abstract]. J Hypertens 1996, 14:S348.
4. Hagmann M, Burnier M, Nussberger J, Leenhardt AF, Brouard R, Waeber B, et al.: Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers [abstract]. Am J Hypertens 1994, 7:13A.
5. Martinez F, Schmitt F, Savoiu C, Leenhardt AF, Brouard R, Peronnet P, et al: Effect of SR 47436 (BMS 186295) on renal hemodynamics and on glomerular permselectivity in healthy humans [abstract]. J Am Soc Nephrol 1994, 5:607.
6. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL: Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996, 28:101-106.
7. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R: Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) [abstract]. J Hypertens 1994, 12:S92.
8. van den Meiracker AH, Admiraal PJJ, Janssen JA, Kroodsma J-M, de Ronde WAM, Boomsma F, et al.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995, 25:22-29.
9. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, et al.: The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension [abstract]. Am J Hypertens 1996, 9:152A.
10. Rose M, MacMahon FG: Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990, 3:151-155.
11. Lipicky RJ: Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994, 12 (suppl 8):S17-S19.
12. Omboni S, Parati G, Zanchetti A, Mancia G: Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995, 13:1105-1112.
13. White WB: Analysis of ambulatory blood pressure data in antihypertensive drug trials. J Hypertens 1991, 9:S27-S32.
14. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A: Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995, 8:311-315.
15. Mancia G, Sega R, Bravi C, DeVito G, Valagussa F, Cesana G, et al.: Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995, 13:1377-1390.
16. Zanchetti A: Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens 1994, 12 (suppl 8):S97-S106.
17. Mancia G, Omboni S, Parati G, Trazzi S, Mutti E: Limited reproducibility of hourly blood pressure values obtained by ambulatory blood pressure monitoring: implications for studies on antihypertensive drugs. J Hypertens 1992, 10:1531-1535.
18. Joint National Committee: The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993, 153:154-183.
19. Zanchetti A, Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, et al.: 1993 Guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension Meeting. Hypertension 1993, 22:392-403.